Great Lakes Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

Great Lakes Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$303K	Buy	+23,752	New	+$306K	﹤0.01%	707

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

LCM

Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

SIC

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Great Lakes Advisors's TNXP Position: Q2 2026 in Review

Great Lakes Advisors opened a new position in Tonix Pharmaceuticals (TNXP) in Q2 2026: 23,752 shares worth $303K. The stake represents ﹤0.01% of the portfolio and ranks #707 among its holdings.

36 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

Great Lakes Advisors held 23,752 shares of Tonix Pharmaceuticals worth $303K as of Q2 2026.
Tonix Pharmaceuticals was a new Great Lakes Advisors position in Q2 2026.
Tonix Pharmaceuticals made up ﹤0.01% of Great Lakes Advisors's portfolio in Q2 2026, its #707 holding.
36 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.